Call for proposals to support the development of a medicine pricing, reimbursement and access tracker through the EURIPID database

Grant Purpose and Target

• Core Objective: To support the development of a medicine pricing, reimbursement, and access tracker through the European Integrated Price Information Database (EURIPID). The goal is to improve the availability, accessibility, and affordability of medicines in the EU by enhancing transparency and supporting mutual learning between national authorities.
• Funding Organization: European Health and Digital Executive Agency (HaDEA), on behalf of the European Commission.
• Target Recipients: The grant specifically targets public authorities from EU Member States and associated countries that are members of the EURIPID collaboration and are competent in the domain of pricing and reimbursement of medicines.
• Sector Focus: SECTOR-SPECIFIC, focusing on public health, pharmaceutical policy, and data management within government bodies.
• Geographic Scope: Applicants must be established in EU Member States (including overseas countries and territories) or in EEA countries and countries associated with the EU4Health Programme. The project activities must take place in these eligible countries.
• Key Filtering Criteria:
  • Consortium: A consortium of at least 4 beneficiaries from 3 different eligible countries is mandatory.
  • Applicant Type: Applicants must be EURIPID members and public authorities responsible for medicine pricing and reimbursement.
  • Project Scale: The project budget is expected to be around €750,000, with a single grant awarded. The project duration should be between 24 and 36 months.

Financial Structure

• Funding Range: The total available budget for this topic is €750,000, and the funding body expects to award a single grant. Therefore, the project budget is expected to be around this amount.
• Co-financing: The funding rate is up to 60% of the eligible costs. This rate can be increased to a maximum of 80% for actions of 'exceptional utility'. The criteria for exceptional utility may include projects where at least 30% of the budget is allocated to Member States with a low GNI per capita.
• Eligible Costs: Costs must be directly linked to the project and necessary for its implementation. Eligible direct costs include:
  • Personnel costs: For employees, natural persons under direct contract, and seconded persons.
  • Subcontracting costs.
  • Purchase costs: Including travel and subsistence, equipment (depreciation costs), and other goods, works, and services (e.g., consumables, dissemination materials).
  • Indirect costs: A flat rate of 7% of the total eligible direct costs is applied.
• Ineligible Costs: In addition to standard ineligible costs (e.g., debt service, provisions for losses, currency exchange losses), this call explicitly prohibits financial support to third parties.
• Payment & Reporting: Payments are structured with an initial pre-financing, potential interim payments linked to periodic reports, and a final payment. The coordinator receives the funds and is responsible for distributing them to other beneficiaries. A Certificate on the Financial Statements (CFS) produced by an independent auditor is required for any beneficiary requesting an EU contribution of €325,000 or more.

Eligibility Requirements

• Formal Criteria:
  • Applicants (beneficiaries and affiliated entities) must be legal entities (public or private bodies, although the target is explicitly public authorities).
  • Applicants must be established in an EU Member State (including OCTs) or an eligible non-EU country (listed EEA countries and countries associated with the EU4Health Programme).
  • Proposals must be submitted by a consortium of at least 4 applicants from at least 3 different eligible countries.
  • Participants must be registered in the EU's Participant Register before submission.
• Organizational Status: Applicants should be EURIPID members and public authorities with competence in the pricing and reimbursement of medicines. International organisations are also eligible to apply.
• Technical Expertise: Applicants must demonstrate they have the necessary know-how, qualifications, and resources to implement the project. This is assessed based on the competence and experience of the project teams, including their expertise in pharmaceutical policy, data management, and IT systems, as evidenced by staff profiles and a list of previous projects.
• Exclusion Criteria:
  • Applicants subject to EU exclusion decisions or in situations such as bankruptcy, grave professional misconduct, or breach of tax/social security obligations are not eligible.
  • Financial support to third parties is explicitly not allowed under this topic.

Application Practical Information

• Deadlines:
  • Call Opening: 23 September 2025
  • Submission Deadline: 06 January 2026, 17:00:00 CET (Brussels time)
  • Evaluation Period: January – March 2026
  • Notification of Results: April – May 2026
  • Grant Agreement Signature: September – October 2026
• Required Documents: The proposal must be submitted electronically and must include:
  • Application Form Part A: Contains administrative information and a summarized budget, filled in online.
  • Application Form Part B: The technical description of the project, submitted as a PDF with a strict page limit of 70 pages.
  • Mandatory Annexes:
    • A detailed budget table/calculator.
    • Curriculum Vitae (CVs) of core project team members.
    • A list of key previous projects from the last 4 years.
• Application Process: Submission is a single-stage process managed entirely through the EU Funding & Tenders Portal's Electronic Submission System.
• Support: For questions related to the call, applicants can contact the funding agency at [email protected]. The Funding & Tenders Portal also provides an IT Helpdesk, FAQ, and an Online Manual for procedural guidance.
• Post-Award Obligations:
  • Reporting: Beneficiaries must provide continuous reporting via the portal tools and submit periodic technical and financial reports as scheduled in the Grant Agreement.
  • Record-Keeping: All records and supporting documents must be kept for 5 years after the final payment.
  • Communication: Projects must acknowledge EU funding and display the European flag and funding statement in all communication and dissemination materials.

Evaluation Criteria

Proposals are evaluated in a one-stage process and scored out of 100 points. To be considered for funding, proposals must pass both the minimum score for each criterion and an overall minimum score of 70.

• Scoring Factors:

  • Relevance (30 points): This criterion assesses the clarity and consistency of the project's objectives and activities, its alignment with the call's priorities, its contribution to the EU's strategic and legislative context, and the European/trans-national dimension of the project. A minimum score of 21 is required.
  • Quality — Project design and implementation (30 points): This covers the technical quality of the proposal, the logical link between identified problems and proposed solutions, the feasibility of the methodology, and the cost-effectiveness of the plan. A minimum score of 21 is required.
  • Quality — Project team and cooperation arrangements (30 points): Evaluates the quality and complementarity of the consortium members and their project teams, as well as the appropriateness of the proposed management and cooperation procedures. A minimum score of 21 is required.
  • Impact (10 points): Assesses the ambition and expected effects of the project on target groups and the general public, the quality of the communication and dissemination strategy, and the sustainability of the project's results after EU funding ends. A minimum score of 7 is required.

• Tie-breaking: For proposals with the same total score, priority will be given based on the score for the 'Relevance' criterion.

• Innovation & Impact: The project is expected to deliver a significant impact by providing EURIPID members with a better overview of medicine access and P&R measures, supporting mutual learning, and ultimately improving the availability and affordability of medicines across the Union. The 'Impact' criterion specifically scores the project's ambition and sustainability.
• Project Quality: Assessed under the two 'Quality' criteria, focusing on a sound methodology, feasible work plan, strong management structure, and a clear quality assurance and evaluation strategy.
• Strategic Fit: The 'Relevance' criterion is designed to measure how well the project fits with the call's objectives, which include implementing the EU4Health Programme and supporting the Pharmaceutical Strategy for Europe.
• Cross-cutting Themes: The application must address Ethics, describing any potential issues and mitigation measures. Compliance with data protection regulations is essential given the nature of the data handled. The project must also uphold basic EU values such as human dignity, freedom, and democracy.

Compliance and Special Requirements

• Regulatory Compliance:
  • Ethics: The project must adhere to the highest ethical standards. The application requires a description of any ethical issues and the measures planned to address them.
  • Data Protection: As the project involves processing data on medicine pricing, compliance with applicable data protection laws, including GDPR (Regulation 2016/679), is mandatory.
• IP Policy: In line with the Model Grant Agreement, the beneficiaries retain ownership of the results they generate. However, they must grant the EU a royalty-free, non-exclusive, irrevocable licence to use project-related materials (e.g., deliverables, summaries, reports) for communication, dissemination, and policy purposes. This includes the right to distribute, edit, translate, and archive the materials. Specific rules in Annex 5 of the Grant Agreement may apply, covering exploitation, open access to research data (FAIR principles), and access rights for policy purposes.
• Unique Aspects:
  • This action is a continuation of a previous EU4Health project (HS-g-22-17.01), and timely launch is crucial to ensure the continuity of the EURIPID database's functions.
  • The eligibility is highly specific, limited to public authorities that are members of the EURIPID collaboration.
  • The project duration is strictly set between 24 and 36 months.
• Industry-Specific Rules: While not for commercial industry, the project operates within the highly regulated pharmaceutical and healthcare policy sector. All activities must align with EU and national laws governing medicinal products and pricing transparency.